Seven Fleet Portfolio Shift
Seven Fleet Capital Management Expands Healthcare Holdings While Trimming Minerva Stake
Anonymous
Key Points
1
In Celcuity, Seven Fleet’s second-quarter activity increased the stake to 16,252 shares (a 170.9% rise) worth about $1.7 million, while other institutional investors also expanded positions: Quantinno Capital Management LP to 243,042 shares (~$3.245 million) and Paloma Partners Management Co to 82,137 shares (~$1.097 million), together contributing to institutional ownership of 63.33%.
2
In Amylyx Pharmaceuticals, Seven Fleet acquired 14,540 shares (valued at about $261,138,000), while insider Gina Mazzariello sold 15,000 shares on July 9 at an average price of $18.32, reducing her stake to 194,090 shares valued at roughly $3,555,728.80.
3
Seven Fleet added 13,800 shares of the iShares U.S. Medical Devices ETF (IHI), valued at about $682,000; IHI is a BlackRock-managed ETF that tracks the DJ US Select Medical Equipment index.
4
Roivant Sciences received a substantial increase, with Seven Fleet’s stake rising 71.7% to 220,126 shares after buying 91,958 more; the holding is worth about $7.79 million and accounts for roughly 1.3% of the portfolio, ranking as the fund’s 17th largest holding.
5
Seven Fleet trimmed Minerva Neurosciences by about 12% in 2Q, selling 136,357 shares and ending with 1,001,373 shares worth roughly $5.558 million, making NERV about 0.9% of the portfolio.
Seven Fleet Capital Management LP pivoted its healthcare portfolio in the second quarter, boosting stakes in biotech and medical-device companies while pulling back from smaller biopharma plays. The fund grew its Celcuity position by 170.9% to 16,252 shares and added 14,540 shares of Amylyx Pharmaceuticals, signaling aggressive moves into high-risk therapeutic bets. At the same time, Seven Fleet trimmed Minerva Neurosciences by 12%, selling 136,357 shares and reflecting a selective retreat from underperforming positions watchlistnews.
Celcuity and Roivant Become Top Growth Bets
Seven Fleet's biggest move was turbocharging Celcuity, with the stake jumping to 16,252 shares worth roughly $1.7 million. The 170.9% increase placed the fund alongside other institutional buyers ramping up exposure watchlistnews. Roivant Sciences also saw aggressive buying, with Seven Fleet's position rising 71.7% to 220,126 shares valued at approximately $7.79 million. Roivant now ranks as the fund's 17th largest holding, accounting for about 1.3% of the portfolio watchlistnews.
Amylyx Entry and Insider Selling Signal Mixed Signals
Seven Fleet entered Amylyx Pharmaceuticals by acquiring 14,540 shares valued at approximately $261.1 million, betting on the biotech's pipeline watchlistnews. The move came as insider Gina Mazzariello sold 15,000 shares on July 9 at an average price of $18.32, reducing her stake to 194,090 shares. The insider's simultaneous exit and Seven Fleet's entry suggest divergent views on the stock's near-term direction watchlistnews.
Broader Medical-Equipment Play via iShares ETF
Beyond individual stock picks, Seven Fleet added $682,000 worth of exposure to the iShares U.S. Medical Devices ETF (IHI), purchasing 13,800 shares watchlistnews. The BlackRock-managed fund tracks the Dow Jones U.S. Select Medical Equipment index, offering diversified access to medical-equipment makers. The move signals Seven Fleet's desire to hedge single-stock risk while staying exposure to the medical-device sector watchlistnews.
Minerva Retreat Marks Exit From Smaller Biopharma
Seven Fleet cut Minerva Neurosciences by 12%, selling 136,357 shares and leaving 1,001,373 shares worth approximately $5.6 million watchlistnews. Minerva now represents just 0.9% of the portfolio, down from a larger position. The trim reflects Seven Fleet's selective pruning of smaller biopharma holdings that have underperformed, clearing capital for higher-conviction picks like Celcuity and Roivant watchlistnews.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
18
Articles
11
Reach
29
Topics
A
AnonymousAuthor
